Rosetta Genomics this week announced that it has begun to accept fine-needle aspirate cell block samples for analysis using its miRview Squamous test, which uses microRNA signatures to differentiate squamous from non-squamous non-small-cell lung cancer.
"FNA is a less invasive method to obtain tumor cells compared with tumor resections or biopsies … [enabling] patients and physicians to benefit from a highly accurate diagnostic assay without having to undergo a more invasive procedure," the company said.